MedTrace Logo

A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.

NCT00269828 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2020-11-24

No results posted yet for this study

Summary

This is a randomized, open-label, multinational, phase III study in women with histologically- or cytologically-confirmed advanced NSCLC who are chemotherapy naïve and have PS 2. Study drug will be administered on day 1 of each 21 day cycle

Conditions

Interventions

DRUG

paclitaxel

DRUG

paclitaxel poliglumex

Sponsors & Collaborators

  • CTI BioPharma

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Completion
2006-12-31

Countries

  • United States
  • Argentina
  • Bulgaria
  • Canada
  • Hungary
  • Mexico
  • Poland
  • Romania
  • Russia
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00269828 on ClinicalTrials.gov